Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Sanofi Exploring Acquisition of KRAS Cancer Drugmaker Mirati

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Oct 09, 2023 4:20pm

144 Views

Post# 35676149

RE:Sanofi Exploring Acquisition of KRAS Cancer Drugmaker Mirati

canadafan still keeps pulling his facts out of a hat. For instance this is just one fact check on accelerated approval vs fast track as canadafan claimed. Read this thread for the rest.

Mirati is in the process of rolling out its first product to patients, a drug called Krazati that’s used as a second-line treatment for a type of lung cancer in which the the KRAS gene has mutated. The company received accelerated approval from the Food and Drug Administration for the drug in December 2022.

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023